Compare Amplify Transformational Data Sharing ETF (BLOK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Incyte Corporation — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.71, while Incyte Corporation trades at $121.12 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | INCY | |
|---|---|---|
52-Week High | $74.10 | $129.93 |
52-Week Low | $47.36 | $81.61 |
Market Cap | — | $24.54B |
Sector | — | Health |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with a bearish technical signal from moving averages but neutral oscillators. Support lies at $59 and resistance at $61. The ETF's financial ratios are not disclosed, and a small dividend of $0.08 is scheduled for June 2026. Recent news highlights institutional trimming and focus on AI infrastructure holdings.
Outlook remains cautious due to bearish technicals and lack of fundamental data. Risks include sector volatility and institutional selling. Opportunities may arise from AI-driven growth in portfolio companies, but investors should await clearer financial metrics for valuation.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
